BAX vs VTRS vs SKYA Stock Comparison

Baxter International, Viatris and SkyAI Prices as of Oct 27, 2026 Peers: Industry group
BAX Baxter International Inc
$24.92 +6.6% 1M +7.6% 1Y
Market cap
$13.34B
P/E
–
Revenue (TTM)
$5.55B
Div. yield
0.01%
Medical Supplies Healthcare
1 win
VTRS Viatris Inc
$18.72 +5.0% 1M +79.7% 1Y
Market cap
$21.86B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
–
Generic Drugs Healthcare
7 wins
SKYA SkyAI, Inc.
$2.91 +54.8% 1M -46.2% 1Y
Market cap
$212.68M
P/E
–
Revenue (TTM)
$194.22K
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

10 decided of 12

Viatris leads on 7 of the 12 questions below (Viatris 7, SkyAI 2, Baxter International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBAXVTRSSKYALeader
Larger companyMarket capitalisation $13.34B $21.86B $212.68M VTRS
Cheaper on earningsLower P/E, profitable companies only -12.5x -53.2x -0.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.6x 7.1x 0.0x SKYA
Faster revenue growthRevenue growth, trailing twelve months -49.1% +4.4% +108.9% SKYA
More profitableNet margin, trailing twelve months -19.2% -2.8% -158,431.4% VTRS
Better return on capitalReturn on invested capital 3.4% -0.2% — BAX
Less leveragedLower net debt / EBITDA 4.8x 4.6x — VTRS
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.6% +79.7% -46.2% VTRS
Better 5-year returnAnnualised price return, 5 years -20.5%/yr +7.0%/yr — VTRS
Less volatileAnnualised volatility, 1 year 44.3% 32.4% 106.0% VTRS
Higher overall scoreMean of the five percentile scores vs peers 44/100 66/100 26/100 VTRS

Percentile Scorecard

BAXVTRSSKYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBAXVTRSSKYA
Valuation 83 #40 of 227 93 #44 of 625 2 #222 of 227
Growth 19 #177 of 219 48 #314 of 602 6 #205 of 219
Profitability 72 #58 of 206 81 #104 of 551 1 #204 of 206
Financial Health 19 #193 of 238 23 #508 of 656 95 #14 of 238
Shareholder Returns 26 #99 of 134 85 #54 of 365 –
Overall 44 66 26
  • BAX ranked among 247 companies in Medical Devices and Diagnostics
  • VTRS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBAXVTRSSKYASPY
1 month +6.6%+5.0%+54.8% -0.2%
3 months +2.3%+4.8%+107.9% +3.9%
6 months +38.9%+26.3%+62.6% +8.2%
Year to date +30.4%+50.4%+43.3% +12.9%
1 year +7.6%+79.7%-46.2% +12.3%
3 years -22.5%+113.5%-99.9% +87.4%
3 years, per year -8.2%+28.8%-90.1% +23.3%
5 years -68.3%+40.4%— +67.9%
5 years, per year -20.5%+7.0%— +10.9%
10 years -46.8%-50.8%— +261.1%
10 years, per year -6.1%-6.8%— +13.7%

Risk

MeasureBAXVTRSSKYASPY
Volatility, 1Y 44.3%32.4%106.0% 12.7%
Downside volatility, 1Y 48.0%29.6%104.5% 12.7%
Beta vs S&P 500, 1Y 1.160.702.59 1.00
Return / volatility, 1Y 0.172.46-0.44 0.97
Max drawdown, 5Y -82.3%-52.9%-100.0% -25.4%
From 52-week high -12.1%0.0%-46.2% -1.2%
52-week high $28.35$18.72$5.41 $779.14
52-week low $15.80$10.11$0.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBAXVTRSSKYA
P/E now vs peer median -12.1xmedian 29.6x -53.0xmedian 17.2x -0.7xmedian 29.6x
P/S now vs peer median 2.3xmedian 2.9x 1.5xmedian 9.0x 1,080xmedian 2.9x
EV/EBITDA now vs peer median 13.4xmedian 17.4x 12.5xmedian 16.3x —median 17.4x
P/FCF now vs peer median 15.4xmedian 22.3x 11.0xmedian 18.7x —median 22.3x
P/B now vs peer median 2.1xmedian 2.3x 1.5xmedian 2.2x 1.3xmedian 2.3x
PEG now vs peer median -0.42median 1.04 1.73median 0.33 0.01median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBAXVTRSSKYA
Revenue $5.55B $14.74B $194.22K
Gross profit $3.78B $5.13B $321.93K
Operating income $532.00M -$87.30M -$289.52M
Net income -$1.06B -$410.70M -$307.71M
Free cash flow $839.00M $1.95B –
R&D $542.00M $1.02B $399.91K
EPS (diluted) $-2.05 $-0.35 $-4.27
Cash & equivalents $2.15B $886.50M $12.07M
Total debt $9.46B $13.35B –
Shares (diluted) 518.00M 1.16B 72.09M
Enterprise value $5.47B $16.88B $171.38M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBAXVTRSSKYA
P/E -12.1x -53.0x -0.7x
P/FCF 15.4x 11.0x –
P/Operating cash flow 9.6x 9.2x –
P/S 2.3x 1.5x 1,080x
P/B 2.1x 1.5x 1.3x
P/Tangible book 6.0x 36.8x 16.1x
EV/EBITDA 13.4x 12.5x –
EV/EBIT 38.0x -389.1x -0.7x
EV/Revenue 3.6x 2.3x 1,018x
EV/FCF 24.1x 17.4x –
EV/Operating cash flow 15.0x 14.6x –
PEG (3Y EPS CAGR) -0.42 1.73 0.01

Growth

14 metrics
MetricBAXVTRSSKYA
Revenue growth (1Y) -49.1% 4.4% 108.9%
Revenue CAGR (3Y) -23.5% -1.9% 23.8%
Gross profit growth (1Y) -1.8% -0.7% –
Gross profit CAGR (3Y) -5.2% -6.0% –
Operating income growth (1Y) -50.8% 96.6% -5,525%
Operating income CAGR (3Y) 29.5% -27.6% -212.8%
Net income growth (1Y) -604.0% 88.2% -42,440%
Net income CAGR (3Y) 28.0% -30.5% -238.0%
EPS growth (1Y) -580.5% 88.1% -487.2%
EPS CAGR (3Y) 28.6% -30.6% -84.2%
Operating cash flow growth (1Y) 56.3% 12.9% –
Operating cash flow CAGR (3Y) -4.8% -3.0% –
Free cash flow growth (1Y) 153.5% 11.6% –
Free cash flow CAGR (3Y) -9.5% -3.6% –

Profitability

14 metrics
MetricBAXVTRSSKYA
Gross margin 68.1% 34.8% 165.8%
EBITDA margin 27.3% 18.4% –
Operating margin 9.6% -0.6% -149,065%
Pretax margin 5.1% -4.5% -151,352%
Net margin -19.2% -2.8% -158,431%
FCF margin 15.1% 13.3% –
Operating cash flow margin 24.2% 15.8% –
Return on equity -17.4% -2.8% -140.2%
Return on assets -5.4% -1.1% -137.6%
Return on invested capital 3.4% -0.2% –
Return on capital employed 3.3% -0.3% -136.7%
Asset turnover 0.3x 0.4x 0.0x
Cash conversion (OCF / net income) -1.3x -5.7x –
Stock comp / revenue 2.1% 1.2% 48,037%

Financial Health

11 metrics
MetricBAXVTRSSKYA
Debt / assets 47.8% 38.1% –
Debt / equity 1.5x 0.9x –
Net debt / EBITDA 4.8x 4.6x –
Debt / FCF 11.3x 6.8x –
Liabilities / assets 68.6% 59.3% 1.9%
Equity / assets 31.4% 40.7% 98.1%
Interest coverage – -0.2x –
Current ratio 1.9x 1.6x 5.3x
Quick ratio 1.1x 0.7x 4.4x
Cash ratio 0.6x 0.1x 4.2x
Altman Z-score 2.12 1.15 31.41

Shareholder Returns

7 metrics
MetricBAXVTRSSKYA
Dividend yield 0.2% 2.6% –
Net buyback yield -0.2% 1.4% –
Shareholder yield 0.0% 4.0% –
Payout ratio (earnings) -17.3% – –
Payout ratio (FCF) 21.9% – –
Dividend growth (1Y) -60.8% – –
Dividend CAGR (3Y) -32.0% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBAXVTRSSKYA
Forward P/E 12.6xFY2026 7.1xFY2026 0.0xFY2026
EPS, next fiscal year $1.98FY2026 $2.62FY2026 $2,362.06FY2026
EPS growth, next FY -10.4%FY2026 +11.5%FY2026 –
EPS growth, the year after -3.5% -1.5% –
Revenue, next fiscal year $11.05BFY2026 $15.31BFY2026 $70.01MFY2026
Revenue growth, next FY -1.7%FY2026 +7.0%FY2026 +34,200.1%FY2026
Revenue growth, the year after +11.7% -4.8% +17.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBAXVTRSSKYA
Held by institutions 100.0% 89.9% –
Institutions holding 690 1,028 –
Change in shares held, QoQ +5.2% +5.6% –
Institutions buying 359 486 –
Institutions selling 193 318 –
Buyers to sellers 1.86 1.53 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BAXVTRSSKYA
BAX 1.00 0.30 0.11
VTRS 0.30 1.00 0.04
SKYA 0.11 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BAX, VTRS and SKYA?

Viatris (VTRS) is the largest by market capitalisation: Baxter International (BAX) $13.34B, Viatris (VTRS) $21.86B, SkyAI (SKYA) $212.68M.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Baxter International (BAX) -49.1%, Viatris (VTRS) +4.4%, SkyAI (SKYA) +108.9%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Baxter International (BAX) -19.2%, Viatris (VTRS) -2.8%, SkyAI (SKYA) -158,431.4%). On return on invested capital, Baxter International (BAX) leads (Baxter International (BAX) 3.4%, Viatris (VTRS) -0.2%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Baxter International (BAX) +7.6%, Viatris (VTRS) +79.7%, SkyAI (SKYA) -46.2%. Over five years, Viatris (VTRS) compounded fastest (Baxter International (BAX) -20.5%/yr, Viatris (VTRS) +7.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Baxter International (BAX) 0.01%, Viatris (VTRS) 0.00%, SkyAI (SKYA) 0.00%. Viatris (VTRS) and SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Baxter International (BAX) 44.3%, Viatris (VTRS) 32.4%, SkyAI (SKYA) 106.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BAX, VTRS and SKYA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.